Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 755.90

+2.6%

Nov 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2107)	5/4/2017 3:06:17 PM
From: Miljenko Zuanic	Read Replies (1) of 3559

From the 1Q CC: <Based on a qualitative market research survey we conducted in the first quarter, EYLEA market share remained consistent at approximately 66% of the FDA-approved anti-VEGF market. Also based on this survey, FDA approved anti-VEGF therapies account for approximately 56% of the overall anti-VEGF market.> How will CMC part B evolve (is anyone guess), but current picture for market share can actually improve for Brand drug usage.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next